Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Search Icon
Search Icon
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Study finds 75% of women treated at ERs after taking abortion pills rated ‘severe or critical’

Women who visit emergency rooms after taking abortion pills are more likely to be seen for serious medical problems than their cohorts whose pregnancies end with surgical abortions or live births, according to newly released research.

A peer-reviewed study of Medicaid-eligible women by researchers at the pro-life Charlotte Lozier Institute found they were “significantly more likely to have a severe or critical acuity rating” within 30 days of using the two-drug abortion protocol than were other women seen at ERs.

That includes women who had recently given birth; undergone surgical abortions or visited the emergency room for any reason, a finding based on 2004-15 data in the 17 states where Medicaid covers abortion expenses.

Continue Reading at the Washington Times >>

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

October 6, 2026
Please login to bookmark Close
Ultrasound image showing the side profile of a human baby

Inside The Government Decision That Opened Up Abortion Pill Floodgates

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
Please login to bookmark Close
A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

October 6, 2026
Please login to bookmark Close

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image